Afhandlingen har titlen 'Targeting the Shared Neoantigens: Potentials of Cancer Immune Therapy in the Chronic Myeloproliferative Neoplasms'.
Forsvaret finder sted i Store Auditorium, Sjællands Universitetshospital, Roskilde, Sygehusvej 10.
The Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) are characterized by a very homogenic mutational landscape, as more than 50 % of the patients harbor the JAK2V617F mutation and 25 % have a mutation in exon 9 of the calreticulin (CALR) gene. Both of these somatic mutations generate tumor specific JAK2-mutant and CALR-mutant neoantigens. Both of these neoantigens are recognized by the immune system and cells displaying these neoantigens are killed by specific T cells. This provides the pre-clinical rationale for cancer immune therapy in the MPN.
Se venligst vedhæftede invitation for flere detaljer : Invitation_til_PhD_forsvar.pdf